Millipore Sigma Vibrant Logo

OP102 Anti-von Hippel-Lindau (VHL) Mouse mAb (Ig33)

Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.
OP102
  
Recuperando precio...
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Maximum Quantity is
Al finalizar el pedido Más información
Ahorró ()
 
—
Solicitar precio
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

       

      Póngase en contacto con el Servicio de Atención al Cliente

      Descripción

      Replacement Information

      Tabla espec. clave

      Host
      M
      Description
      Overview

      This product has been discontinued.





      Recognizes the ~30 kDa von Hippel-Lindau (VHL) protein in prostate, lung, colon, breast, bladder or carcinoma tissue.
      Catalogue NumberOP102
      Brand Family Calbiochem®
      References
      ReferencesCorliss, C.L., et al. 1997.Human Pathology 28, 459.
      Lee, S., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 1770.
      Siemeister, G., et al. 1996. Cancer Res. 56, 2299.
      Tsuchiya, H., et al. 1996. Cancer Res. 56, 2881.
      Chen, F., et al. 1995. Cancer Res. 55, 4804.
      Duan, D.R., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 6459.
      Duan, D.R., et al. 1995. Science 269, 1402.
      Iliopoulos, O., et al. 1995. Nat. Med. 1, 822.
      Kishida, T., et al. 1995. Cancer Res. 55, 4544.
      Kley, N., et al. 1995. Glia 15, 297.
      Wizigmann-Voos, S., et al. 1995. Cancer Res. 55, 1358.
      Product Information
      FormLiquid
      FormulationIn 10 mM PBS, 0.2% BSA, pH 7.4.
      Positive controlProstate, kidney, lung, colon, breast, bladder, or thyroid carcinoma tissue
      Preservative≤0.1% sodium azide
      Applications
      Application ReferencesOriginal Clone Kibel, A., et al. 1995. Science 269, 1444.
      Key Applications Immunoblotting (Western Blotting)
      Paraffin Sections
      Application NotesImmunoblotting (1-2 µg/ml)
      Paraffin Sections (2-4 µg/ml; heat pre-treatment required, see comments)
      Application CommentsPrior to staining formalin-fixed, paraffin-embedded tissue sections, boil the tissue in 1 mM EDTA, pH 8.0, for 10-20 min, followed by cooling at room temperature for 20 min. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogena recombinant fusion protein consisting of amino acids 1-213 of human VHL
      ImmunogenHuman
      CloneIg33
      HostMouse
      IsotypeIgG₁
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Special InstructionsFollowing initial use, aliquot and freeze (-20°C) for long-term storage.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      OP102 0

      Documentation

      Anti-von Hippel-Lindau (VHL) Mouse mAb (Ig33) Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Anti-von Hippel-Lindau (VHL) Mouse mAb (Ig33) Certificados de análisis

      CargoNúmero de lote
      OP102

      Referencias bibliográficas

      Visión general referencias
      Corliss, C.L., et al. 1997.Human Pathology 28, 459.
      Lee, S., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 1770.
      Siemeister, G., et al. 1996. Cancer Res. 56, 2299.
      Tsuchiya, H., et al. 1996. Cancer Res. 56, 2881.
      Chen, F., et al. 1995. Cancer Res. 55, 4804.
      Duan, D.R., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 6459.
      Duan, D.R., et al. 1995. Science 269, 1402.
      Iliopoulos, O., et al. 1995. Nat. Med. 1, 822.
      Kishida, T., et al. 1995. Cancer Res. 55, 4544.
      Kley, N., et al. 1995. Glia 15, 297.
      Wizigmann-Voos, S., et al. 1995. Cancer Res. 55, 1358.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision09-July-2007 RFH
      ApplicationImmunoblotting (1-2 µg/ml)
      Paraffin Sections (2-4 µg/ml; heat pre-treatment required, see comments)
      DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with NS1 mouse myeloma cells (see application references). Recognizes the ~30 kDa von Hippel-Lindau protein (VHL).
      BackgroundVon Hippel-Lindau disease is a rare tumor syndrome that is characterized by cerebellar and spinal hemangioblastomas and retinal angiomas. Molecular studies suggest that VHL is a tumor suppressor gene, which is inactivated or mutated in von Hippel-Lindau disease as well as in clear-cell renal carcinomas (RCC). The gene is affected in both hereditary and in sporadic tumors. In clear-cell renal carcinomas there is loss of function of both copies of the gene suggesting a role in proliferation control. This hypothesis is borne out by the observation that transfection of the wild type protein will inhibit cell growth. Initially identified in 1993, the VHL protein has a bipartite localization, it is found localized to the cytoplasm in densely cultured cells but in the nucleus in sparse cell cultures. The primary functional target of VHL protein is the transcription elongation complex in particular, the elongin proteins B and C which bind in vitro and in vivo to a short, colinear region of the VHL protein that is frequently mutated in human tumors. In addition to the elongins, VHL has been shown to bind to other proteins including the HIV tat-binding protein, filamin and VBP-1, and two other VHL binding proteins, p14 (p16) and p10 (p9). More recently, VHL has been shown to control VEGF expression in several different tumors, affecting primarily the splice variants VEGF121 and VEGF165.
      HostMouse
      Immunogen speciesHuman
      Immunogena recombinant fusion protein consisting of amino acids 1-213 of human VHL
      CloneIg33
      IsotypeIgG₁
      Specieshuman
      Positive controlProstate, kidney, lung, colon, breast, bladder, or thyroid carcinoma tissue
      FormLiquid
      FormulationIn 10 mM PBS, 0.2% BSA, pH 7.4.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsPrior to staining formalin-fixed, paraffin-embedded tissue sections, boil the tissue in 1 mM EDTA, pH 8.0, for 10-20 min, followed by cooling at room temperature for 20 min. Antibody should be titrated for optimal results in individual systems.
      Storage Avoid freeze/thaw
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing initial use, aliquot and freeze (-20°C) for long-term storage.
      Toxicity Standard Handling
      ReferencesCorliss, C.L., et al. 1997.Human Pathology 28, 459.
      Lee, S., et al. 1996. Proc. Natl. Acad. Sci. USA 93, 1770.
      Siemeister, G., et al. 1996. Cancer Res. 56, 2299.
      Tsuchiya, H., et al. 1996. Cancer Res. 56, 2881.
      Chen, F., et al. 1995. Cancer Res. 55, 4804.
      Duan, D.R., et al. 1995. Proc. Natl. Acad. Sci. USA 92, 6459.
      Duan, D.R., et al. 1995. Science 269, 1402.
      Iliopoulos, O., et al. 1995. Nat. Med. 1, 822.
      Kishida, T., et al. 1995. Cancer Res. 55, 4544.
      Kley, N., et al. 1995. Glia 15, 297.
      Wizigmann-Voos, S., et al. 1995. Cancer Res. 55, 1358.
      Application referencesOriginal Clone Kibel, A., et al. 1995. Science 269, 1444.